TY - JOUR
A2 - Fasching, Peter A.
AU - Inwald, E. C.
AU - Ortmann, O.
AU - Zeman, F.
AU - Koller, M.
AU - Hofstädter, F.
AU - Gerstenhauer, M.
AU - Klinkhammer-Schalke, M.
PY - 2014
DA - 2014/03/20
TI - Guideline Concordant Therapy Prolongs Survival in HER2-Positive Breast Cancer Patients: Results from a Large Population-Based Cohort of a Cancer Registry
SP - 137304
VL - 2014
AB - Even though randomized controlled clinical trials demonstrated improved survival by adjuvant trastuzumab treatment of HER2-positive breast cancer patients, data on its effect in clinical routine are scarce. This study evaluated the use and efficacy of trastuzumab in routine treatment of HER2-positive breast cancer patients. Data from the clinical cancer registry Regensburg (Germany) were analyzed. The present study investigated 6,991 female patients with primary invasive breast cancer. In premenopausal HER2-positive patients a considerable increase of trastuzumab therapy was observed from 58.1% in 2006 to 90.9% in 2011, whereas in postmenopausal patients trastuzumab was rather used on a constant rate of 49.1%. Best overall survival (OS) was found in HER2/steroid hormone receptor-positive patients receiving guideline concordant treatment with trastuzumab plus chemotherapy (CHT) plus antihormone therapy (AHT) with a 7-year OS rate of 96% compared to the non-trastuzumab group with a 7-year OS rate of 92%. In multivariable analysis, HER2-positive patients treated with CHT or AHT who did not get trastuzumab, had a worse 7-year OS (65%, P=0.006 versus 79%, P=0.017) than the control groups. This population-based study demonstrated that guideline concordant use of adjuvant trastuzumab improves OS for HER2-positive breast cancer patients treated in routine clinical care.
SN - 2314-6133
UR - https://doi.org/10.1155/2014/137304
DO - 10.1155/2014/137304
JF - BioMed Research International
PB - Hindawi Publishing Corporation
KW -
ER -